Megan L Fitzgerald

US Patent:

20210277403, Sep 9, 2021

Filed:

Feb 26, 2021

Appl. No.:

17/249337

Inventors:

- South San Francisco CA, US
Megan Elizabeth Fitzgerald - San Francisco CA, US
Saul Martinez Montero - San Francisco CA, US
Aneerban Bhattacharya - San Mateo CA, US

International Classification:

C12N 15/113
A61K 45/06
A61P 35/00
A61P 31/20
A61K 31/7105

Abstract:

The present disclosure relates to small interfering RNA (siRNA) molecules directed to mRNA transcripts of CD274 to cause downregulation of programmed death-ligand 1 (PD-L1) expression in humans. The siRNA can be constructed of unmodified nucleotides or modified nucleotides that exhibit modified sugars, nucleobases, linkages, or covalently bound targeting moieties. Also disclosed herein are pharmaceutical compositions of siRNAs and uses of or methods of using the siRNAs for the treatment of PD-L1 related diseases including but not limited to liver diseases, cancer, hepatocellular carcinoma, viral diseases, or hepatitis B.

US Patent:

20210269797, Sep 2, 2021

Filed:

Feb 26, 2021

Appl. No.:

17/249335

Inventors:

- South San Francisco CA, US
Megan Elizabeth Fitzgerald - San Francisco CA, US
Saul Martinez Montero - San Francisco CA, US
Aneerban Bhattacharya - San Mateo CA, US

International Classification:

C12N 15/113
A61K 45/06

Abstract:

The present disclosure relates to antisense oligonucleotides (ASOs) directed to mRNA transcripts of CD274 to cause downregulation of programmed death-ligand 1 (PD-L1) expression in humans. The ASO can be constructed of unmodified nucleotides or modified nucleotides that exhibit modified sugars, nucleobases, linkages, or covalently bound targeting moieties. Also disclosed herein are pharmaceutical compositions of ASOs and uses of or methods of using the ASOs for the treatment of PD-L1 related diseases including but not limited to liver diseases, cancer, hepatocellular carcinoma, viral diseases, or hepatitis B.

US Patent:

20180179542, Jun 28, 2018

Filed:

Nov 13, 2017

Appl. No.:

15/810857

Inventors:

- South San Francisco CA, US
Megan Fitzgerald - South San Francisco CA, US
Antitsa Dimitrova Stoycheva - Half Moon Bay CA, US
Jin Hong - Pacifica CA, US

Assignee:

Alios Biopharma, Inc. - South San Francisco CA

International Classification:

C12N 15/113
A61P 31/20
A61K 31/7125
A61K 45/06

Abstract:

The present disclosure provides oligonucleotide compositions that target the covalently closed circular (ccc) DNA of hepatitis B virus (HBV). Also disclosed herein are methods for treating a subject diagnosed with, or suspected of having an HBV infection and/or an HBV-associated disorder, e.g., chronic hepatitis B infection, liver failure or cirrhosis and hepatocellular carcinoma.